MedTrace Logo

Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective

NCT02221635 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 540

Last updated 2014-08-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation in the prevention of relapse of the symptoms of schizoaffective disorder. Primary Outcome Measures:Time between subject randomization to treatment and the first occurrence of a relapse during the Relapse Prevention Period. Secondary Outcome Measures: Symptom change as measured by the Positive and Negative Syndrome Scale (PANSS) total and PANSS factor scores; Illness severity change as measured by Clinical Global Impression of Severity for depression (CGI-S-DEP); Change in subject functioning using the Personal and Social Performance Scale; Change in subject medication satisfaction using the Medication Satisfaction Questionnaire (MSQ).

Conditions

  • Schizoaffective Disorder

Interventions

PROCEDURE

rTMS + risperidone

Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.

DRUG

Risperidone

Risperidone (2-4 mg) was took orally.

Sponsors & Collaborators

  • The No.3 hospital of PLA

    collaborator UNKNOWN

  • The No.91 hospital of PLA

    collaborator UNKNOWN

  • No. 102 Hospital of Chinese People's Liberation Army

    collaborator OTHER

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Tan QingRong, MD · XiJing Hospital, Xi'An, Shanxi, China

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-12-31
Completion
2015-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02221635 on ClinicalTrials.gov